On June 28, Layn Biology announced in a press release that its subsidiary, Holding, had used its own funds to subscribe to 4,907,590 shares of common stock from Ispire's targeted issuance of unlimited shares. The subscription price was $7.1318 per share. As of now, the targeted issuance by Ispire has been completed, and Layn Biology now holds a total of 705,044 shares in Ispire.
On February 20, 2023, Layn Biotech and its subsidiary invested up to 50 million yuan (RMB) in securities using their own funds. On April 4, 2023 (US time), Layn Biotech's wholly-owned subsidiary, Holding, used approximately 1.5 million US dollars of its own funds to acquire 214,285 shares of Ispire through its initial public offering on the NASDAQ stock exchange at a price of $7.00 per share.
Ispire is a company registered in the United States specializes in the research, design, and sales of e-cigarettes and vaporization products related to cannabis, including industrial hemp.
References:
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
